Exploiting 

the conformational 

complexity of GPCRs 

to innovate 

drug discovery​

 

Confo Therapeutics employs its proprietary CONFO® technology to lock inherently unstable functional conformations of GPCRs as a superior starting point for drug discovery. Confobody-stabilized active state conformations of these receptors reveal previously inaccessible structural features empowering the discovery of novel pathway-selective agonists for improved therapeutic intervention.​

About
Confo Therapeutics​

Confo Therapeutics is a drug discovery company building a unique pipeline of GPCR targeted therapeutics addressing unmet medical need.​

Conformational challenges of GPCR drug discovery​

Understanding the CONFO® technology​

ConfoBody™-

enabled drug

discovery​

Distinguishing features

References

News

Confo Brussels

Pleinlaan 2
Building E, 7th Floor, Room E7.6
1050 Brussels, Belgium

info@confotherapeutics.com

Career

Opportunities

To join our talented team and become a part of our future success, please contact us​

Research

and development

 

Confo Ghent

Technologiepark 94
9052 Ghent/Zwijnaarde, 

Belgium

Confo Therapeutics reports grant of two key ConfoBody™ patents
- 02.12.2019

FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 2019
- 23.09.2019

Confo Therapeutics and DyNAbind announce drug discovery collaboration
- 03.07.2019

Confo Therapeutics receives €1.7 million grant from VLAIO to target an orphan indication
- 20.06.2019

Confo Therapeutics raises €30 million in Series A financing 
- 07.05.2019

Confo Therapeutics forms Scientific Advisory Board as it accelerates development of proprietary drug discovery engine - 28.02.2019

Confo Therapeutics Announces Exclusive License Agreement with VIB for Novel Structure Determination Technology - 03.01.2019

Confo Therapeutics Appoints Frank Landolt as its Chief Counsel Legal & Intellectual Property

06.12.2018

Confo Therapeutics 

is awarded EUR 1 M

20.02.2018

Confo Therapeutics

enters into drug discovery collaboration with Roche

19.12.2017

Investors

Founding Institutes